COVID-19

The facilities will be inspected between March 9 and June 9, 2022.

NACDS CEO responds to comments by AMA president.

President Biden’s recent State of the Union address included a pharmacy Test to Treat iniativie for COVID-19.

Rural areas lag well behind their urban counterparts when it comes to COVID-19 vaccinations

Molnupiravir is an oral antiviral for the treatment of mild to moderate COVID-19 in adults at high risk of severe disease.

COVID-19 updates and news to know as of February 28, 2022.

A large cohort study offers important data on what factors are frequently tied to severe cases of COVID-19 in the pediatric population.

The days of blanket mitigation strategies to protect children from COVID-19 are becoming a thing of the past. One model sheds light onto determining when strategies can be relaxed.

Recent treatment may affect the antibody response, particularly among those with hematologic cancers.

COVID-19 updates and news to know as of February 21, 2022.

Does anxiety justify an exemption from vaccine mandates among health care workers?

Patients with chronic lymphocytic leukemia experienced functional T cell and antibody responses after receiving a vaccine for COVID-19.

NVX-CoV2373 was evaluated in adolescents aged 12 to 17 years.

The FDA meeting to discuss extending the Pfizer/BioNTech EUA to children aged 6 months to 4 years has been postponed until data on a third dose has been studied.

The safety of the Pfizer/BioNTech COVID-19 vaccine in pregnant women, for both mother and baby, has been dependent on observation during the rollout. A large population trial provides further support for the vaccine’s safety.

As respiratory viruses and COVID-19 variants lurk seemingly everywhere, here’s how best to detect and differentiate.

A third dose of an mRNA COVID-19 vaccine was safe and associated with modestly increased levels of antibodies in patients with reduced protective humoral immunity before reimmunization.

COVID-19 updates and news to know as of February 7, 2022.

Pfizer received an emergency use authorization (EUA) for Paxlovid, an oral pill for the treatment of mild to moderate COVID-19 in certain adult and pediatric populations.

Several institutions have published guidance on how to treat patients hospitalized with COVID-19.

Spikevax is now the second COVID-19 vaccine approved by regulators.

NVX-CoV2373 is a protein-based COVID-19 vaccine for adults 18 years and older.

COVID-19 updates and news to know as of January 31, 2022.

Further research is needed to determine causation.

A retrospective cohort study in a research letter published in the Journal of the American Academy of Dermatology examined the risk between atopic dermatitis and COVID-19 risk.